Findakly Dawood, Luther Ross D, Wang Jue
Internal Medicine, Creighton University Arizona Health Education Alliance/Valleywise Health Medical Center, Phoenix, USA.
Urology, Madigan Army Medical Center, Tacoma, USA.
Cureus. 2020 May 29;12(5):e8355. doi: 10.7759/cureus.8355.
Tumor lysis syndrome (TLS) is a life-threatening oncological condition that is typically characterized by metabolic derangements that are often labeled as an acute kidney injury. The recent advancement in cancer treatment has led to the mounting rate of TLS in solid tumors that were previously rarely linked to this complication. Given that its prognosis is dismal, it is essential to increase recognition of this condition by describing more sensitive markers. Currently, the management of TLS is mainly supportive due to the lack of specific therapy targeting its specific pathology. This review aims to summarize the most recent literature on the underlying mechanism of TLS and the potential implications for novel TLS therapy.
肿瘤溶解综合征(TLS)是一种危及生命的肿瘤病症,其典型特征为代谢紊乱,常被视为急性肾损伤。癌症治疗的最新进展导致实体瘤中TLS的发生率不断上升,而实体瘤此前很少与这种并发症相关联。鉴于其预后不佳,通过描述更敏感的标志物来提高对该病症的认识至关重要。目前,由于缺乏针对其特定病理的特异性治疗,TLS的管理主要是支持性的。本综述旨在总结关于TLS潜在机制的最新文献以及对新型TLS治疗的潜在影响。